From chemistry-request %-% at %-% ccl.net Tue Jun 14 12:34:51 2005 Received: from iqpc-ms5.iqpc.loc (mail.iqpc.co.uk [195.167.134.86]) by server.ccl.net (8.13.1/8.13.1) with ESMTP id j5EGYlMa021858 for ; Tue, 14 Jun 2005 12:34:47 -0400 Received: from iqpc-ms4.iqpc.loc ([10.10.5.4]) by iqpc-ms5.iqpc.loc with Microsoft SMTPSVC(6.0.3790.211); Tue, 14 Jun 2005 16:50:31 +0100 X-MimeOLE: Produced By Microsoft Exchange V6.5.7226.0 Content-class: urn:content-classes:message MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----_=_NextPart_001_01C570F8.CB5979EC" Subject: Meeting Hit to Lead Date: Tue, 14 Jun 2005 16:50:31 +0100 Message-ID: <3CCB329C8B224648B4F2E6013B0B62DA1C23A7)at(iqpc-ms4.iqpc.loc> X-MS-Has-Attach: X-MS-TNEF-Correlator: Thread-Topic: Meeting Hit to Lead Thread-Index: AcVwP2onw54k2EnYQvajr/xRn/CYmQ== From: "Ricardo Molina" To: X-OriginalArrivalTime: 14 Jun 2005 15:50:31.0818 (UTC) FILETIME=[CB7E4EA0:01C570F8] X-Spam-Status: No, score=0.9 required=5.0 tests=DEAR_SOMETHING, FORGED_RCVD_HELO,HTML_60_70,HTML_MESSAGE autolearn=no version=3.0.3 X-Spam-Checker-Version: SpamAssassin 3.0.3 (2005-04-27) on server.ccl.net This is a multi-part message in MIME format. ------_=_NextPart_001_01C570F8.CB5979EC Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Dear Sirs, I would like to bring to your attention a conference we are organising in= London that I am sure would be of interest to the CCL.net readers. We ar= e happy to give a special discount of 10% to all those interested in atte= nding from your site. All they have to do is quote CCL when contacting us= =2E Hit-To-Lead Enhancing lead generation to accelerate quality compounds into lead optim= isation July 18 - 19, 2005 =B7 The Caf=E9 Royal, London, UK http://www.iqpc-pharma.com/GB-2484/SPR4 =20 Increasing pressure to reduce attrition and put forward better quality le= ad compounds is forcing hit-to-lead up the agenda of every pharmaceutical= company. Many are now reducing this major bottleneck by improving decis= ion-making and generating better quality leads faster. And Pharma IQ is = showcasing the most innovative and successful case studies at this year's= Hit-to-Lead conference. Leaders from big pharma including Pfizer, Roche= , Novartis, AstraZeneca, Bayer, Wyeth, Merck, Sanofi-Aventis and Johnson = & Johnson will be revealing their stories of success and failure in lead = generation. By taking a practical and in-depth look at their strategies = and experiences, you can enhance your own practices and ensure you are fo= cussing your resources only on the most promising compounds.=20 If you have any questions or are interested in attending please contact m= e on Ricardo.Molina)at(iqpc.co.uk or giv= e us a call on 0207 368 9300. I am happy to extend a special 10% discount= for all CCL members. There is also a special price for Academia. Simply = quote CCL when contacting us. For full conference agenda visit http://www.iqpc-pharma.com/GB-2484/SPR4 = =20 =20 Thank you very much for your time =20 =20 Ricardo Molina=20 Pharma IQ (a division of IQPC) Anchor House 15-19 Britten Street=20 London SW3 3QL=20 e: Ricardo.Molina)at(iqpc.co.uk =20 w: www.iqpc-pharma.com =20 t: +44 (0) 20 7368 9300=20 ************************************************************************=20= This email is confidential and intended solely for the use of the individ= ual to whom it is addressed. Any views or opinions presented are solely t= hose of the author and do not necessarily represent those of IQPC Ltd or = any of its affiliates. If you are not the intended recipient, be advised = that you have received this email in error and that any use, disseminatio= n, forwarding, printing, or copying of this email is strictly prohibited.= If you have received this email in error please notify us by telephone o= n +44 (0)20 7368 9300.=20 This footnote also confirms that this email message has been checked by a= nti-virus software for the presence of computer virii. However, IQPC Ltd = accepts no responsibility for any virus or defect that might arise from o= pening this e-mail or attachments.=20 ************************************************************************=20= ------_=_NextPart_001_01C570F8.CB5979EC Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable
Dear=20= Sirs,

I would like to bring = to your=20 attention a conference we are organising in London that I am sure wo= uld be=20 of interest to the CCL.net=20 readers. We are happy to g= ive a=20 special discount of 10% to all those interested in attending=20 from your site. All they have to do is quote CCL when contacting=20 us.

Hit-To-Lead
Enhanc= ing lead=20 generation to accelerate quality compounds into lead=20 optimisation
July=20 18 - 19, 2005 =B7  The=20 Caf=E9 Royal, London,=20 UK

http://www.iqpc-pharma.com/GB-2484/SPR4

Increasing pressure to reduce attrition and put forward better q= uality=20 lead compounds is forcing hit-to-lead up the agenda of every pharmaceutic= al=20 company.  Many are now redu= cing this=20 major bottleneck by improving decision-making and generating better quality leads=20 faster.  And Pharma = IQ is=20 showcasing the most innovative and successful case studies at this year=92= s=20 Hit-to-Lead conference.  Le= aders=20 > from big pharma including Pfiz= er,=20 Roche, Novartis, AstraZeneca, Bayer, Wyeth, Merck, Sanofi-Aventis and Joh= nson=20 & Johnson will be revealing their stories of success and failu= re in=20 lead generation.  By taking= a=20 practical and in-depth look at their strategies and experiences, you can = enhance=20 your own practices and ensure you are focussing your resources only on th= e most=20 promising compounds.

If=20 you have any questions or are interested in attending please contact me o= n=20 Ricardo.Molina)at(iqpc.co.uk or give us a= call on=20 0207 368 9300. I am happy to extend a special 10% discount for all <= SPAN=20 class=3D054211117-13062005>CCL=20 members. There is also a special price for Academia. Simply quote CCL when contacting=20 us.

For full conference agenda visit http://www.iqpc-pharma.com/GB-2484/SPR4

&n= bsp;

<= SPAN=20 class=3D054211117-13062005>Thank you very much for your=20= time

<= SPAN=20 class=3D054211117-13062005>&nbs= p;

<= SPAN=20 class=3D054211117-13062005>&nbs= p;

<= SPAN=20 class=3D054211117-13062005>

Ricardo=20 Molina=20
Pharma I= Q (a=20 division of IQPC)
Anchor House
15-19 Britten Street=20
London S= W3=20 3QL

e: Ricardo.Molina)at(iqpc.co.uk=20=  
w: www.iqpc-pharma.com
t: +44 (= 0) 20=20 7368 9300=20




= ************************************************************************ =


This email is confidential and intended solely for the use of= the individual to whom it is addressed. Any views or opinions presented = are solely those of the author and do not necessarily represent those of = IQPC Ltd or any of its affiliates. If you are not the intended recipient,= be advised that you have received this email in error and that any use, = dissemination, forwarding, printing, or copying of this email is strictly= prohibited. If you have received this email in error please notify us by= telephone on +44 (0)20 7368 9300.

This footnote also confirms th= at this email message has been checked by anti-virus software for the pre= sence of computer virii. However, IQPC Ltd accepts no responsibility for = any virus or defect that might arise from opening this e-mail or attachme= nts.


********************************************************= **************** ------_=_NextPart_001_01C570F8.CB5979EC--